Lipocine Inc. — Earnings Release 2014

Sep 24, 2014

8-K 1 v389898_8-k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 24, 2014

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware	99-0370688
(State or other jurisdiction of incorporation)	(IRS Employer Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Page; Sequence: 1

Field: /Page

Item 7.01 Regulation FD Disclosures

On September 24, 2014, Lipocine Inc. issued a press release to report top-line results in its Phase 3 study of LPCN 1021 for oral testosterone replacement therapy. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

Additionally, the Company is conducting a conference call and webcast reporting the results from its Phase 3 study of LPCN 1021 on September 24, 2014 beginning at 8:45 a.m. Eastern Time. Participants can access the conference call by dialing 1-877-407-9708. Participants may also access the webcast via the following link, https://event.webcasts.com/starthere.jsp?ei=1044036 . The Company’s materials to be used in the conference call and webcast presentation are attached hereto as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this report:

Exhibit No.	Description
99.1	Press Release Announcing Positive Top-Line Results in Lipocine's Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy
99.2	Phase 3 Top-Line Results Presentation

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Mahesh V. Patel
Mahesh V. Patel
President and Chief Executive Officer

Field: Page; Sequence: 3; Options: Last

Field: /Page